Role of fluoroquinolones in the treatment of tuberculosis

Abstract

Introduction: The increasing incidence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of

Appropriateness of antimicrobial selection for treatment of pneumonia in selected public hospitals of Eastern Ethiopia: A cross-sectional study

“…A Clinical perspective would suggest that this was a reasonable strategy. With the risk of delayed tuberculosis diagnosis and treatment, as well as the emergence of FQ resistance in Mycobacterium tuberculosis, [46][47][48][49][50][51][52][53][54] the role of fluoroquinolones as empirical therapy for CAP remains questionable in countries with high tuberculosis burden. Furthermore, even though doxycycline in combination with a β-lactam is associated with similar or better outcomes in terms of mortality in patients hospitalized with pneumonia, [55][56][57] it should be reserved as an alternative to macrolides in patients with mild to moderate CAP, particularly in settings where it is difficult to assess the previous history of antimicrobial use.…”

New Perspectives in the Diagnosis and Treatment of Tuberculosis

“…Both, currently existing drugs already approved for human use and new drugs with novel mechanism of action are in various stages of development for shortening treatment duration of drug-susceptible TB and to improve outcome of MDR-TB/ Phase II clinical trials are underway with daily administration of high-dose rifampin (1200 mg) for shortening treatment duration of drug-susceptible TB to 4 months [18]. Phase II trials have also been completed and phase III trials are currently underway to evaluate whether treatment of newly diagnosed, drug sensitive adult, pulmonary TB can be shortened to 4 months by substitution of gatifloxacin for ethambutol or moxifloxacin for either ethambtol or isoniazid [19]. The combination of amoxicillin/clavulanate plus meropenem is synergistically active against MDR-TB/XDR-TB.…”